Washington, DC - “We know that academic investigators, small and medium enterprises, and sometimes even large companies can have questions regarding the path from preclinical to clinical development for biological products – particularly those that raise new regulatory questions,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research (CBER). “As part of our commitment to help accelerate the development and approval of innovative medical products, the FDA has implemented the INTERACT meeting program, designed to foster timely engagement with CBER on issues critical to early product development. It’s also aimed at helping innovators meet the FDA’s science-based requirements more effectively.

Washington, DC - At the request of the Federal Trade Commission and the state of Nevada, a federal court has ordered that a revenge porn site be permanently shut down, and that the operators pay more than $2 million after finding they violated federal and state law by posting intimate images of people and their personal information without their consent and charging takedown fees.

Washington, DC - The U.S. Department of Energy (DOE) announced an agreement with New Zealand’s Ministry of Business, Innovation and Employment (MBIE) to collaborate on the advancement of geothermal technologies.

Washington, DC - The U.S. Department of Agriculture’s (USDA) Food Safety and Inspection Service (FSIS) is conducting a survey to help enhance the creation and delivery of information and resources for small and very small meat and poultry processing and slaughter establishments.

Washington, DC - The United States expresses serious concern about the role of Malian military forces in the deaths of 25 people, as acknowledged by Defense Minister Tiena Coulibaly. We support Minister Coulibaly’s decision to immediately open an investigation. We call on the Government of Mali to ensure that the investigation into this and other serious allegations of human rights violations and abuses are conducted in a credible and transparent manner and result in accountability as appropriate.

Washington, DC - The U.S. Food and Drug Administration Thursday approved the Eversense Continuous Glucose Monitoring (CGM) system for use in people 18 years of age and older with diabetes. This is the first FDA-approved CGM system to include a fully implantable sensor to detect glucose, which can be worn for up to 90 days.